Page 11 - MRS Abstracts March 2023

• Treat-to-target clinics will improve gout management, reduce hospitalisation and be cost- effective in the long run.
Acknowledgement:
We appreciate the record department of New Cross Hospital, Royal Wolverhampton NHS Foundation Trust, for providing the information requested promptly.
Conflict of interest: All authors have no conflict of interest
Table 1 Demographic characteristics and univariate analysis (Chi-square/Mann Whitney U test)
Variables
Total (n=399) n(%)
Hospitalised (n=328) n(%)
Not Hospitalised (n=71) n(%)
OR (95% CI)
P-Value
Age
67 (53-82)*
70 (54-83)*
58 (52-70)*
< 0.001
Gender M
F
308 (77.2) 91 (22.8)
254 (63.7) 74 (18.5)
54 (13.5) 17 (4.3)
1.08 (0.59- 1.98)
0.801
Race Caucasians Non-Caucasians
303 (75.9) 96 (24.9)
253 (63.4) 75 (18.8)
50 (12.5) 21 (5.3)
0.97 (0.42- 2.27)
0.078
Types Tophaceous Not tophaceous
53 (13.3) 346 86.7)
32 (8.0) 296 (74.2)
21 (5.3) 50 (12.5)
0.26 (0.14- 0.48)
<0.001
SUA at diagnosis Median (IQR) SUA now Median (IQR)
496 (452- 577)* 471 (386- 573)*
496 (453- 575)* 477 (390- 575)*
496 (444- 585)* 412 (295- 510)*
0.964
0.002
Allopurinol
Yes
No
259 (64.9) 140 (35.1)
208 (52.1) 120 (30.1)
51 (12.8) 20 (5.0)
0.74 (0.41- 1.33)
0.312
Dosage of allopurinol
50-300 mg 400-600 mg
Median (IQR)
238 (59.6) 21 (5.3) 200 (100- 300)*
191 (47.9) 17 (4.2) 100 (100- 300)*
47 (11.7) 4 (1.0) 200 (100- 300)*
0.175
Febuxostat
Yes
No Median (IQR)
15 (3.8) 384 (96.2) 80 (80-80)*
10 (2.5) 318 (79.7) 80 (80-80)*
5 (1.3)
66 (16.5) 80 (80-80)*